Browsing by Author "Guner, Gurkan"

Now showing 1 - 3 of 3

Association Between Body Mass Index and Survival in Patients With De Novo Metastatic Non-Small Cell Lung Cancer
(int Scientific information, inc, 2024) Urun, Muslih; Guner, Gurkan; Sezgin, Yasin; Sakin, Abdullah; Kilickap, Saadettin
Background: This retrospective study from a single center included 289 patients diagnosed with advanced non-small cell lung cancer (NSCLC) between 2010 to 2017 and aimed to evaluate the effects of body mass index (BMI) on overall survival. Material/Methods: This retrospective study involved 289 patients diagnosed with metastatic-stage NSCLC at a single institution between January 2010 and December 2017. Patients were categorized into 2 groups based on their BMI at diagnosis: those with a BMI <25 kg/m(2) and those with a BMI >= 25 kg/m(2). Univariate and multivariate Cox regression analyses were conducted to identify factors associated with overall survival. Results: A total of 289 patients (241 men, 48 women) were included in the study, with a mean age of 60.1 +/- 11.1 years. Among them, 175 patients (60.6%) had a BMI less than 25 kg/m(2). Multivariate analysis revealed that BMI, pathological diagnosis, and complete response after first-line treatment were independently associated with survival in patients with lung cancer. Predicted survival time was significantly shorter in the BMI <25 group than in the BMI >= 25 group (9.3 months vs 13.0 months, P<0.05). Conclusions: The study demonstrated that a higher BMI at the time of diagnosis is associated with improved overall survival in patients with de novo metastatic NSCLC. BMI may serve as an important prognostic factor in this patient population. Future prospective, multi-center studies are necessary to further validate the role of BMI in predicting survival outcomes in NSCLC patients across different treatment modalities.
Comparison of the Efficacy of Dual Chemotherapy Regimens in Second-Line Treatment of Metastatic Esophageal Squamous Cell Carcinoma
(2024) Guner, Gurkan; Sezgin, Yasin
Objectives: This study aimed to compare the efficacy of folinic acid plus 5-fluorouracil plus irinotecan (FOLFIRI), carboplatin plus paclitaxel, and cisplatin plus 5-FU regimens in second-line treatment of metastatic esophageal squamous cell cancer. Methods: The study included patients over the age of 18 with a diagnosis of esophageal squamous cell carcinoma, stage 4 disease, who had progressed after first-line chemotherapy treatment for metastatic disease and received a dual chemotherapy regimen as a second-line chemotherapy. Results: The mean age of 58 patients was 56.4±12.3 years and 33 (56.9%) of them were women. Among 58 patients, 18 received carboplatin plus paclitaxel, 25 received cisplatin plus 5-FU and 15 received FOLFIRI regimen. Second-line chemotherapy responses were 6.9% complete, 41.4% partial, 17.2% stable, and 34.5% of the patients developed pro- gression. The median follow-up was 4.5 mo (0-46 mo). The median OS for all cohort was 14 mo (95% CI, 4.38-23.62) and there was no statistically difference between three groups (p=0.737). Conclusion: In our study, we observed that doublet chemotherapy regimens were effective in the second series treat- ment of metastatic squamous cell carcinoma and may be a good option for patients with good performance status and no access to immunotherapy.
Vincamine Mitigates Methotrexate-Induced Liver Fibrosis Model
(AVES, 2025) Urun, Yonca Yilmaz; Guner, Gurkan; Bora, Ejder Saylav; Taskin, Ayse Buket; Urun, Muslih; Erbas, Oytun
Background/Aims: Liver fibrosis is linked to higher rates of death and disease. This study examined the hepatoprotective properties of vincamine and its potential therapeutic application in treating liver damage caused by methotrexate in rats. Materials and Methods: Thirty male Wistar albino rats, with weights ranging from 150 to 200 g and ages between 10 and 12 weeks, were included in the study. A total of 10 rats were selected to serve as the control group, receiving no medication. A group of 20 rats was given a single intraperitoneal dose of 20 mg/kg methotrexate in order to cause liver damage. Subsequently, the participants were randomly allocated into 2 cohorts and administered either 1 mL/kg/day tap water or 50 mg/kg/day vincamine orally through gavage on a daily basis for a duration of 10 days. Following the completion of the treatment period, the animals were euthanized and their livers were examined histologically. Furthermore, the levels of plasma galectin-3 (gal-3), cytokeratin 18, malondialdehyde (MDA), alanine transaminase (ALT), liver MDA, and transforming growth factor beta (TGF-beta) levels were evaluated. Results: Treatment with vincamine resulted in a significant decrease in plasma gal-3, cytokeratin, MDA, and ALT levels and liver MDA and TGF-beta levels compared to the methotrexate and saline group. Vincamine treatment effectively protected against liver injury, and histopathological examination of the livers confirmed these results. Conclusion: This study demonstrates that vincamine alleviates methotrexate-induced liver toxicity via exhibiting antioxidant, antiinflammatory, and anti-fibrotic activities and improved liver functionally, biochemically, and histopathologically.